CX 3 CR1 Is Dispensable for Control of Mucosal Candida albicans Infections in Mice and Humans
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Candida albicans is part of the normal commensal microbiota of mucosal surfaces in a large percentage of the human population. However, perturbations of the host's immune response or bacterial microbiota have been shown to predispose individuals to the development of opportunistic Candida infections. It was recently discovered that a defect in the chemokine receptor CX 3 CR1 increases susceptibility of mice and humans to systemic candidiasis. However, whether CX 3 CR1 confers protection against mucosal C. albicans infection has not been investigated. Using two different mouse models, we found that Cx3cr1 is dispensable for the induction of interleukin 17A (IL-17A), IL-22, and IL-23 in the tongue after infection, as well as for the clearance of mucosal candidiasis from the tongue or lower gastrointestinal (GI) tract colonization. Furthermore, the dysfunctional human CX 3 CR1 allele CX 3 CR1-M280 was not associated with development of recurrent vulvovaginal candidiasis (RVVC) in women. Taken together, these data indicate that CX 3 CR1 is not essential for protection of the host against mucosal candidiasis, underscoring the dependence on different mammalian immune factors for control of mucosal versus systemic Candida infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Granulomatous Disease: Report on a National Registry of 368 Patients
Winkelstein, J. A., Marino, M. C., Johnston, R. B., Boyle, J., Curnutte, J., Gallin, J. I., Malech, H. L., Holland, S. M., Ochs, H., Quie, P., et al. (2000) · Medicine · doi:10.1097/00005792-200005000-00003 · Cited by 1,728
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Conti, H. R., Shen, F., Nayyar, N., Stocum, E., Sun, J. N., Lindemann, M. J., Ho, A. W., Hai, J. H., Yu, J. J., Jung, J. W., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081463 · Cited by 1,024
A Homozygous CARD9 Mutation in a Family with Susceptibility to Fungal Infections
Glocker, E.-O., Hennigs, A., Nabavi, M., Schäffer, A. A., Woellner, C., Salzer, U., Pfeifer, D., Veelken, H., Warnatz, K., Tahami, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810719 · Cited by 800 · cited 1×
“The only immune factor known to date to confer heightened susceptibility to both mucosal and systemic candidiasis on humans is CARD9, attesting to the central positioning of this adaptor protein downstream of several C-type lectin receptors (30, 36).”
BackgroundBoisson, B., Wang, C., Pedergnana, V., Wu, L., Cypowyj, S., Rybojad, M., Belkadi, A., Picard, C., Abel, L., Fieschi, C., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.09.002 · Cited by 293
Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections
Conti, H. R., Peterson, A. C., Brane, L., Huppler, A. R., Hernández-Santos, N., Whibley, N., Garg, A. V., Simpson-Abelson, M. R., Gibson, G. A., Mamo, A. J., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130877 · Cited by 254
CX3CR1-dependent renal macrophage survival promotes Candida control and host survival
Lionakis, M. S., Swamydas, M., Fischer, B. G., Plantinga, T. S., Johnson, M. D., Jaeger, M., Green, N. M., Masedunskas, A., Weigert, R., Mikelis, C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci71307 · Cited by 230
Self-citationIL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells
Bär, E., Whitney, P. G., Moor, K., Reis e Sousa, C., & LeibundGut-Landmann, S. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.002 · Cited by 197
Fluconazole-Resistant Candida albicans Vulvovaginitis
Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K. S., & Sobel, J. D. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827307b2 · Cited by 195 · cited 1×
“to available antifungal agents that limits therapeutic options (7) highlight the importance of a better understanding of the cellular and molecular immune factors that mediate effective anti-Candida host defense at the mucosa and systemically, with an aim to develop immune-based strategies for risk stratification, pro…”
BackgroundSelf-citationInflammatory Monocytes Orchestrate Innate Antifungal Immunity in the Lung
Espinosa, V., Jhingran, A., Dutta, O., Kasahara, S., Donnelly, R., Du, P., Rosenfeld, J., Leiner, I., Chen, C.-C., Ron, Y., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003940 · Cited by 169
Cited by
Immune defence against Candida fungal infections
Netea, M. G., Joosten, L. A. B., van der Meer, J. W. M., Kullberg, B.-J., & van de Veerdonk, F. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3897 · Cited by 642
Self-citationPathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
Self-citationCX3CR1 + mononuclear phagocytes control immunity to intestinal fungi
Leonardi, I., Li, X., Semon, A., Li, D., Doron, I., Putzel, G., Bar, A., Prieto, D., Rescigno, M., McGovern, D. P. B., et al. (2018) · Science · doi:10.1126/science.aao1503 · Cited by 289
Candida albicans induces mucosal bacterial dysbiosis that promotes invasive infection
Bertolini, M., Ranjan, A., Thompson, A., Diaz, P. I., Sobue, T., Maas, K., & Dongari-Bagtzoglou, A. (2019) · PLOS Pathogens · doi:10.1371/journal.ppat.1007717 · Cited by 176
Aberrant type 1 immunity drives susceptibility to mucosal fungal infections.
Break, T. J., Oikonomou, V., Dutzan, N., Desai, J. V., Swidergall, M., Freiwald, T., Chauss, D., Harrison, O. J., Alejo, J., Williams, D. W., et al. (2021) · Science · doi:10.1126/science.aay5731 · Cited by 175
Self-citation
Metadata
- Authors
- Break, T. J., Jaeger, M., Solis, N. V., Filler, S. G., Rodriguez, C. A., Lim, J. K., Lee, C.-C. R., Sobel, J. D., Netea, M. G., & Lionakis, M. S.
- Venue
- Infection and Immunity
- Publisher
- American Society for Microbiology
- Published
- 2015-03
- Volume
- 83
- Issue
- 3
- Pages
- 958-965
- ISSN
- 0019-9567 (ISSN-L)
- 1098-5522
- OpenAlex
- W1963593559
- Cited by
- 34
- References
- 13
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CX 3 CR1 Is Dispensable for Control of Mucosal Candida albicans Infections in Mice and Humans. https://app.cochat.ai/papers/10.1128/iai.02604-14
- The paper
- Break, T. J., Jaeger, M., Solis, N. V., Filler, S. G., Rodriguez, C. A., Lim, J. K., Lee, C.-C. R., Sobel, J. D., Netea, M. G., & Lionakis, M. S. (2015). CX 3 CR1 Is Dispensable for Control of Mucosal Candida albicans Infections in Mice and Humans. Infection and Immunity. https://doi.org/10.1128/iai.02604-14
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.